Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odetiglucan - HiberCell

Next Previous
Drug Profile

Odetiglucan - HiberCell

Alternative Names: B-glucan PGG; BTH-1677; Imprime; Imprime PGG; Soluble beta glucan - HiberCell

Latest Information Update: 26 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; HiberCell; Mayo Clinic; Merck Sharp & Dohme
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dectin 1 stimulants; Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Non-small cell lung cancer; Triple negative breast cancer
  • Phase I Adenocarcinoma; Liver metastases
  • Suspended Infections
  • No development reported Follicular lymphoma
  • Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Head and neck cancer; Malignant melanoma; Myelosuppression; Stem cell mobilisation

Most Recent Events

  • 04 Mar 2024 HiberCell terminates a phase I trial in Adenocarcinoma (Combination therapy, Metastatic disease, Second line therapy or greater) in USA (IV) due to sponsor decision (NCT05484011)
  • 12 Apr 2023 HiberCell in collaboration with Merck completes a phase II trial in Breast cancer (Combination therapy, Second line therapy or greater, Late-stage study, Metastatic disease) in USA (NCT05159778)
  • 08 Feb 2023 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top